WolverHeme Happy Hour

In this episode, Anthony and Bernie are joined by the great Dr. Bixby to discuss the difficulties in the diagnosis and treatment of acute leukemias of mixed or ambiguous lineage (ALAL/MPAL).
We discuss:
- Diagnostic uncertainties and how the criteria for diagnosis have changed over the years
- Data behind the optimal treatment of MPAL and uncertainties in the literature
- Promising data for the FLAG-VIPR hybrid regimen and other novel treatment strategies

In this episode, Bernie and Anthony are joined by Myeloma Man Manni Mohyuddin, MD to discuss the debate surrounding the treatment of first relapse in multiple myeloma. Should we be using CAR-T? Bispecifics? How does the new mezigdomide data from ASCO 2026 inform our practice? Listen in for a spicy discussion!

Articles discussed:
Nature Reviews Commentary: https://www.nature.com/articles/s41571-026-01159-6
CARTITUDE-4: https://www.nature.com/articles/s41571-026-01159-6
MajesTEC-3: https://www.nejm.org/doi/full/10.1056/NEJMoa2514663
MajesTEC-9: https://www.nejm.org/doi/abs/10.1056/NEJMoa2603870
Control arms in multiple myeloma trials: https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2026020329/567836/Improving-Control-Arms-in-2026-U-S-Myeloma-Trials
Predictors for CAR T cell therapy-associated immune-related adverse events? https://pubmed.ncbi.nlm.nih.gov/41540109/
Dex prophylaxis for lymphocytosis: https://ashpublications.org/bloodadvances/article/10/10/3629/567462/Dexamethasone-prophylaxis-for-excessive-lymphocyte
Mezi-KD vs. KD ASCO 2026: https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA7506

“However much we flatter ourselves about our individual rationality, a good story, no matter how analytically deficient, lingers in the mind, resonates emotionally, and persuades more than the most dispositive facts or data.”
Inspired by the article "The impact of cult behavior on haematopoietic cell transplant practices: believers and non-believers" (https://www.nature.com/articles/s41409-021-01473-w), in this episode, Anthony and Bernie are joined by transplant experts Tate Feeney, PharmD, BCOP and Aaron "Papa heme" Goodman, MD, to discuss "cult-like thinking" in hematology and BMT. We discuss why this occurs, go through some provocative examples, and talk about how to identify bias or ”cult-like thinking” in our own practices!
Grab your favorite drink and prepare to join the wolverheme cult!

In this special video episode, Bernie and Anthony moderate a Common Sense Oncology discussion of key trials from ASH 2025! We are joined by special guest experts from across the globe to critically appraise the abstracts and discuss how they may or may not have changed clinical practice:
Dr. Eddie Cliff (Australia) - Lymphoma
Dr. Roberta Demichelis (Mexico) - Leukemia
Dr. Manni Mohyuddin (USA) - Myeloma
Join the Common Sense Oncology movement here! https://commonsenseoncology.org/get-involved/

In this episode, Anthony and Bernie are joined by a panel of experts to discuss (and debate) everyone's favorite (or most feared) hematology topic - hemophagocytic lymphohistiocytosis (HLH)!
Joining us on this spicy episode are:
- Justin Kaner, MD
- Madeleine Ochs, PharmD, BCOP
- Catherine Johnson, PharmD, BCOP

How should we manage these patients? H-Scores or HLH2004 criteria? What is the role for ruxolitinib? Emapalumab? CXCL9 levels? Grab your favorite drink and have a listen!